Adial Pharmaceuticals (ADIL) Projected to Post Earnings on Tuesday

Adial Pharmaceuticals (NASDAQ:ADIL) is anticipated to release its results before the market opens on Tuesday, March 3rd. Analysts expect Adial Pharmaceuticals to post earnings of ($0.08) per share for the quarter.

Adial Pharmaceuticals Price Performance

Shares of NASDAQ:ADIL opened at $2.33 on Tuesday. Adial Pharmaceuticals has a 1 year low of $2.30 and a 1 year high of $32.50. The stock has a market capitalization of $2.59 million, a price-to-earnings ratio of -0.12 and a beta of 1.26. The company’s 50 day simple moving average is $5.00 and its 200 day simple moving average is $7.43.

Institutional Trading of Adial Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC bought a new position in shares of Adial Pharmaceuticals in the 3rd quarter valued at $51,000. Jane Street Group LLC grew its position in Adial Pharmaceuticals by 887.3% during the 4th quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock worth $27,000 after acquiring an additional 109,500 shares during the last quarter. Finally, Armistice Capital LLC acquired a new position in Adial Pharmaceuticals in the 4th quarter worth about $562,000. Institutional investors own 16.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. UBS Group set a $8.00 target price on Adial Pharmaceuticals in a report on Wednesday, February 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research note on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $22.75.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.